London, UK, and Wilmington, NC, US, March 18, 2013: Chiltern International Limited
(Chiltern), a global contract research organization (CRO), announced that SOTIO a.s. has
selected Chiltern International Limited to be the CRO that carries out the European part of
its phase III global clinical trial entitled VIABLE, which will include 1,170 prostate cancer
patients from Europe and the U.S.
Under the agreement signed in December 2012, Chiltern will be responsible for providing
full-service management of the VIABLE phase III clinical trial in Europe. It will be the
contracting party for 126 treatment centers in 17 European countries where a total of 750
patients are expected to participate in the trial. Chiltern will also be responsible for
processing the data obtained during this clinical evaluation.
Dr Jim Esinhart, CEO, Chiltern, commented, “I am very pleased that we have been
selected to manage this high profile trial. I believe it underscores the strengths and
expertise of our global Oncology Therapeutic Area Team. We look forward to working in
close partnership with SOTIO a.s. to deliver a quality outcome.”
Established in 1982, Chiltern is a leading global clinical CRO with extensive experience in
the management of Phase I-IV clinical trials across a broad range of therapeutic areas,
functional service provision and contract staffing solutions. Chiltern has conducted trials in
more than 40 countries, employs more than 1,500 people globally and offers services in
Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory
Affairs and Resourcing Solutions. Chiltern prides itself as a development partner that offers
flexibility, responsiveness and quality delivery. Further information is available at:
About SOTIO a.s.
Based in Czech Republic, SOTIO is a biotechnology company that is developing next
generation Best-in-Class Active Cellular Immunotherapy (“ACI”), focusing on the treatment
of cancer and autoimmune diseases. The company is in the process of developing new
medical therapies using an immunotherapy platform based on activated dendritic cells with
the view to significantly improving these treatments and making them available to patients.
Further information is available at: www.sotio.com
Natalie Chong, Marketing Director
Chiltern International Ltd.
171 Bath Road 1
Slough, Berkshire SL1 4AA, UK
Tel: +44 (0) 1753 512 000
Susan Ojanen, Marketing Executive
Chiltern International Inc.
241 Volunteer Parkway, Suite 950
Bristol, TN 37620, USA
Tel: +1 (423) 968 9533